$PMVP News

PMV Pharmaceuticals: Restoring Mutant P53 Could Create A Mispriced Cancer Opportunity

PMV Pharmaceuticals Appoints Matt Eckler, Ph.D., to Board of Directors

Should You Buy PMV Pharmaceuticals, Inc. (PMVP) After Golden Cross?

PMV Pharmaceuticals Appoints Philip Herman as Chief Commercial Officer

PMV Pharma Raises $50.8 Million to Fuel Cancer Drug Push

PMV Pharma Raises $50.8 Million to Fuel Cancer Drug Push

PMV Pharma Announces Pricing of Oversubscribed $50 Million Public Offering of Securities

PMV Pharmaceuticals Reports Updated Rezatapopt Ovarian Cancer Data, Commences Offering

PMV Pharma Announces Proposed Public Offering of Securities

PMV Pharmaceuticals Announces Updated Promising Rezatapopt Monotherapy Interim Ovarian Cancer Data From PYNNACLE Phase 2 Pivotal Trial

PMV Pharmaceuticals (PMVP) Upgraded to Buy: What Does It Mean for the Stock?

PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights

PMV Pharma Q2 EPS $(0.34) Beats $(0.39) Estimate

PMV Pharmaceuticals (PMVP) Upgraded to Buy: Here's Why

PMV Pharmaceuticals (PMVP) Loses 26% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

12 Health Care Stocks Moving In Wednesday's After-Market Session

Oppenheimer Maintains Outperform on PMV Pharmaceuticals, Lowers Price Target to $5

PMV Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Highlights

PMV Pharma Q1 EPS $(0.34) Beats $(0.39) Estimate

PMV Pharmaceuticals Announces Board Chair Transition